Last $0.88 USD
Change Today 0.00 / 0.00%
Volume 3.2K
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Snapshot

Open
$0.87
Previous Close
$0.88
Day High
$0.88
Day Low
$0.85
52 Week High
08/5/14 - $2.25
52 Week Low
04/29/14 - $0.02
Market Cap
45.4M
Average Volume 10 Days
34.0K
EPS TTM
--
Shares Outstanding
51.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENUMERAL BIOMEDICAL HOLDINGS (ENUM)

Related News

No related news articles were found.

enumeral biomedical holdings (ENUM) Related Businessweek News

No Related Businessweek News Found

enumeral biomedical holdings (ENUM) Details

Enumeral Biomedical Holdings, Inc. discovers and develops novel antibody immunotherapies that help immune system to attack diseased cells. It focuses on developing a pipeline of product candidates (immunomodulators) for the treatment of cancer and inflammatory diseases. The company was formerly known as Enumeral Biomedical Corp. and changed its name to Enumeral Biomedical Holdings, Inc. in August 2014. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

enumeral biomedical holdings (ENUM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $250.0K
Co-Founder and Executive Chairman
Total Annual Compensation: $200.0K
Vice President of Business Development and Se...
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2013.

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Biomedical Holdings, Inc. and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology with Advanced Prototype System for Human Tissue Immuno-Oncology Profiling

Enumeral Biomedical Holdings, Inc. announced that the company signed an agreement with Memorial Sloan Kettering Cancer Center as part of Enumeral’s Phase II Small Business Innovation Research contract with the National Cancer Institute. Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer. Enumeral’s Phase II program is focused on applying its human-driven immune profiling platform to small volume clinical specimens such as core biopsy or fine needle aspirates, which often contain limited numbers of cells and can be challenging to analyze with conventional technologies. Enumeral’s human-driven immune profiling platform has the ability to determine cellular function in an unbiased fashion, allowing analysis of rare immune cells associated with disease or drug response in even the smallest clinical samples. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response, which may ultimately guide development of more precisely targeted immunotherapies. Enumeral’s collaboration with MSK is supported by a Phase II SBIR contract from the NCI for $999,967 over two years. The NCI is funding the entirety of the program, which complements Enumeral’s other internal research and development efforts. Enumeral demonstrated proof of concept in this area under a Phase I contract in 2012 and 2013.

Enumeral Biomedical Holdings, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-18-2015 through Jan-21-2015

Enumeral Biomedical Holdings, Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-18-2015 through Jan-21-2015. Venue: Club Med, Sandpiper Bay, Florida, United States. Presentation Date & Speakers: Jan-19-2015, Arthur Tinkelenberg, Co-Founder, Chief Executive Officer, President and Director.

Enumeral Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Enumeral Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $0.88 USD 0.00

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies
 

Industry Analysis

ENUM

Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 156.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 127.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit www.enumeral.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.